Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Single-dose, Pharmacokinetic Study of Mitapivat in Subjects With Moderate Hepatic Impairment Compared to Matched Healthy Control Subjects With Normal Hepatic Function

NCT05610657 is registered in ClinicalTrials.gov with Agios Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05610657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05610657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Single-dose, Pharmacokinetic Study of Mitapivat in Subjects With Moderate Hepatic Impairment Compared to Matched Healthy Control Subjects With Normal Hepatic Function
Lead sponsor
Agios Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 10, 2023
Completion date
July 21, 2023
Enrollment
20 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

moderate hepatic impairment